Page last updated: 2024-10-15

gramicidin a

Description

Gramicidin: A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132269
CHEMBL ID601118
SCHEMBL ID10321483
MeSH IDM0009594

Synonyms (20)

Synonym
gramicidin
valyl gramicidin a
einecs 234-259-8
PRESTWICK_799
gramicidin a
11029-61-1
gnf-pf-2578 ,
CHEMBL601118
l-tryptophanamide, n-formyl-l-valylglycyl-l-alanyl-d-leucyl-l-alanyl-d-valyl-l-valyl-d-valyl-l-tryptophyl-d-leucyl-l-tryptophyl-d-leucyl-l-tryptophyl-d-leucyl-n-(2-hydroxyethyl)-
1-l-valinegramicidin a
valinegramicidin a
gramicidin a, 1-l-valine-
4419-81-2
93AG3Q5T2V ,
SCHEMBL10321483
unii-93ag3q5t2v
J-002412
gramicidin a from bacillus brevis, >=90% (hplc)
DTXSID80891352
Q27271585

Research Excerpts

Overview

Gramicidin A (gA) is a hydrophobic pentadecapeptide readily incorporating into a planar bilayer lipid membrane (BLM), thereby inducing a large macroscopic current across the BLM. It disrupts the transmembrane ion concentration gradient by forming an ion channel in a lipid bilayer.

ExcerptReference
"Gramicidin A (gA) is a hydrophobic pentadecapeptide readily incorporating into a planar bilayer lipid membrane (BLM), thereby inducing a large macroscopic current across the BLM. "( Peptide-induced membrane elastic deformations decelerate gramicidin dimer-monomer equilibration.
Akimov, SA; Antonenko, YN; Batishchev, OV; Kondrashov, OV; Kotova, EA; Rokitskaya, TI, 2021
)
"Gramicidin A (1) is a peptide antibiotic that disrupts the transmembrane ion concentration gradient by forming an ion channel in a lipid bilayer. "( Discovery of gramicidin A analogues with altered activities by multidimensional screening of a one-bead-one-compound library.
Hamamoto, H; Inoue, M; Itoh, H; Panthee, S; Paudel, A; Sekimizu, K; Takada, Y, 2020
)
"Gramicidin A (gA) is a short β-helical peptide known to form conducting channels in lipid membranes because of transbilayer dimerization. "( Membrane Elastic Deformations Modulate Gramicidin A Transbilayer Dimerization and Lateral Clustering.
Akimov, SA; Antonenko, YN; Galimzyanov, TR; Kondrashov, OV; Kotova, EA; Pavlov, KV, 2018
)
"Gramicidin A is a channel-forming ionophore that forms a hydrophilic membrane pore that permits the rapid passage of monovalent cations."( Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma.
Bremner, RM; David, JM; Inge, LJ; Owens, TA; Rajasekaran, AK, 2014
)
"Gramicidin A (gA) is a polypeptide antibiotic, which forms dimeric channels specific for monovalent cations in artificial and biological membranes. "( Large scale conformational transitions in β-structural motif of gramicidin A: kinetic analysis based on CD and FT-IR data.
Ivanov, VT; Sychev, SV, 2014
)
"Gramicidin A is an antimicrobial peptide that destroys gram-positive bacteria. "( The antimicrobial activity of gramicidin A is associated with hydroxyl radical formation.
Chen, YC; Hung, YJ; Liou, JW; Yang, CH, 2015
)
"Gramicidin A is a linear hydrophobic 15-residue peptide which consists of alternating D- and L-amino acids and forms a unique tertiary structure, called the beta(6.3)-helix, to act as a cation-selective ion channel in the natural conditions. "( Folding simulations of gramicidin A into the beta-helix conformations: Simulated annealing molecular dynamics study.
Mori, T; Okamoto, Y, 2009
)
"Gramicidin A (gA) is a 15-amino-acid antibiotic peptide with an alternating L-D sequence, which forms (dimeric) bilayer-spanning, monovalent cation channels in biological membranes and synthetic bilayers. "( Influence of hydrophobic mismatch on structures and dynamics of gramicidin a and lipid bilayers.
Andersen, OS; Im, W; Kim, T; Lee, KI; Morris, P; Pastor, RW, 2012
)
"Gramicidin A (gA) is a polypeptide antibiotic which forms dimeric channels specific for monovalent cations in biological membranes. "( Size-exclusion high-performance liquid chromatography in the study of the autoassociating antibiotic gramicidin A in micellar milieu.
Abad, C; Bañó, MC; Salom, D, 2003
)
"Gramicidin A (gA) is a linear pentadecapeptide, which exhibits various conformations depending on the environment. "( Conformation of gramicidin-A in CTAB micellar media.
Chandra, N; Mishra, AK; Shobini, J,
)
"Gramicidin A is a pentadecapeptide that functions as a transmembrane channel for transporting monovalent ca"( Molecular structure and mechanisms of action of cyclic and linear ion transport antibiotics.
Duax, WL; Griffin, JF; Grochulski, P; Ivanov, V; Langs, DA; Pletnev, V; Smith, GD, 1996
)
"Gramicidin A is an antibiotic peptide produced by Bacillus brevis ATCC 8185, which also produces tyrocidines. "( Enzyme-bound formylvaline and formylvalylglycine; an initiation complex for gramicidin A biosynthesis.
Akashi, K; Kurahashi, K, 1978
)
"Gramicidin A is a pentadecapeptide that functions as a transmembrane channel for transporting monovalent cations."( Molecular conformation and ion transport of cyclic and linear ionophores.
Duax, WL; Ivanov, VT; Langs, DA; Pangborn, WA; Pletnev, VZ; Smith, GD, 1989
)

Effects

ExcerptReference
"Gramicidin A' (GA') has been added to three lipid systems of varying hydrophobic thicknesses: dimyristoyllecithin (DML), dipalmitoyllecithin (DPL), and distearoyllecithin (DSL). "( Hydrophobic mismatch in gramicidin A'/lecithin systems.
Chan, SI; Dea, P; Watnick, PI, 1990
)

Actions

ExcerptReference
"Gramicidin also promotes HII phase formation in the PE system but interacts much less strongly with PE than with PC."( 2H-nuclear magnetic resonance investigations on phospholipid acyl chain order and dynamics in the gramicidin-induced hexagonal HII phase.
Chupin, V; de Kruijff, B; Killian, JA, 1987
)

Treatment

ExcerptReference
"Gramicidin A-treated tumors also displayed physiologic and molecular features consistent with the inhibition of HIF-dependent angiogenesis."( Gramicidin A blocks tumor growth and angiogenesis through inhibition of hypoxia-inducible factor in renal cell carcinoma.
Bremner, RM; David, JM; Inge, LJ; Owens, TA; Rajasekaran, AK, 2014
)

Toxicity

ExcerptReference
"The membrane-active ionophores were observed to possess antifungal activity against Candida albicans 336 and were toxic to human erythrocytes."( A comparison of in vitro toxicity and antifungal efficacy of membrane-active drugs after liposome encapsulation.
Hopfer, RL; Juliano, RL; Lopez-Berestein, G; Mehta, RT, 1989
)
"The sea nettle jellyfish toxin (SNTX), which contains several polypeptides, was highly toxic to human hepatocytes."( Toxicity of sea nettle toxin to human hepatocytes and the protective effects of phosphorylating and alkylating agents.
Burnett, JW; Cao, CJ; Eldefrawi, AT; Eldefrawi, ME; Menking, DE; Mioduszewski, RJ; Valdes, JJ, 1998
)
"Studies were conducted using a novel in vitro approach to investigate the efficacy of acetamidine hydrochloride (ACE) and guanidine hydrochloride (GUAN), previously shown to block gramicidin D (GRAM) channels in artificial membranes, in preventing the toxic effects of GRAM in NG108-15 (neuroblastoma x glioma hybrid) cells."( Gramicidin toxicity in NG108-15 cells: protective effects of acetamidine and guanidine.
Doebler, JA, 1999
)
"Cerebellar granule cells (CGCs) express K+-dependent (NCKX) and K+-independent (NCX) plasmalemmal Na+/Ca2+ exchangers which, under plasma membrane-depolarizing conditions and high cytosolic [Na+], may reverse and mediate potentially toxic Ca2+ influx."( In depolarized and glucose-deprived neurons, Na+ influx reverses plasmalemmal K+-dependent and K+-independent Na+/Ca2+ exchangers and contributes to NMDA excitotoxicity.
Czyz, A; Kiedrowski, L, 2002
)
" Seven toxic or allergic reactions were reported."( The efficacy and safety of topical polymyxin B, neomycin and gramicidin for treatment of presumed bacterial corneal ulceration.
Bosscha, MI; Jager, MJ; Kuijper, EJ; Swart, W; van Dissel, JT, 2004
)
"This study shows that the combination of polymyxin B, neomycin, and gramicidin is an effective and safe treatment of suspected corneal ulceration."( The efficacy and safety of topical polymyxin B, neomycin and gramicidin for treatment of presumed bacterial corneal ulceration.
Bosscha, MI; Jager, MJ; Kuijper, EJ; Swart, W; van Dissel, JT, 2004
)
" We tested whether the NCX or NCKX family of exchangers contributes most to the toxic NMDA-induced Ca(2+) influx in depolarized neurons."( Differential contribution of plasmalemmal Na/Ca exchange isoforms to sodium-dependent calcium influx and NMDA excitotoxicity in depolarized neurons.
Baranauskas, G; Czyz, A; Kiedrowski, L; Li, XF; Lytton, J, 2004
)
" Toxicity assessment of new 1,2,4-triazoles revealed significant differences in their toxic potential, and the results indicate the same sensitivity profile among the assays as observed with the standard compounds."( Assessing the data quality in predictive toxicology using a panel of cell lines and cytotoxicity assays.
Pohjala, L; Samanta, SK; Tammela, P; Vuorela, P; Yli-Kauhaluoma, J, 2007
)

Compound-Compound Interactions

ExcerptReference
" This study demonstrated synergistic antifungal activity of free and liposomal forms of AmpB when combined with the free and liposomal forms of gramicidin S and gramicidin NF against five Candida strains."( Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF.
Hopfer, RL; Lopez-Berestein, G; Mehta, R, 1987
)

Bioavailability

ExcerptReference
" Impairment of glucose bioavailability reduced Rh 123 fluorescence."( Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry.
Camarasa, J; Camins, A; Comas, J; Escubedo, E; Gabriel, C; Sureda, FX, 1997
)
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)

Dosage Studied

ExcerptReference
" 3) Decreasing K+ efflux using K+ channel blockers (4-aminopyridine, quinine, sparteine) inhibited histamine release in a dose-response manner."( Regulation of human basophil activation. II. Histamine release is potentiated by K+ efflux and inhibited by Na+ influx.
Beauvais, F; Benveniste, J; Burtin, C; Hieblot, C; Inoue, I; Shimahara, T, 1992
)
" Fruit essence and sugar had a significant effect on the results of gramicidin S biological activity determination as compared to the other components of the dosage form."( [Effect of the extraction methods and drug form components on the determination of gramicidin C in buccal tablets].
Golubkova, LS; Grigor'eva, VM; Poliak, MS; Rezvaia, MI; Vasil'va, NG, 1980
)
" Total VFA concentration, protozoa numbers, and NDF digestibility were not depressed significantly at this dosage but were reduced at 100 mg/d with little further increase in the molar percentage of propionate."( Effect of aibellin, a peptide antibiotic, on propionate production in the rumen of goats.
Hino, T; Kanda, M; Kumazawa, S; Miwa, T; Saitoh, H, 1994
)
" The purpose of this study was to determine the dose-response effects of G-D, N9, EDTA and G-D + EDTA on sperm motion parameters and acrosome status."( Dose-response effects of gramicidin-D, EDTA, and nonoxynol-9 on sperm motion parameters and acrosome status.
Centola, GM, 1998
)
" This study utilized computer-assisted methods to investigate the dose-response effects of incubation with G-D, N-9, EDTA, and G-D plus EDTA on sperm motion parameters and acrosome status."( Dose-response effects of gramicidin-D, EDTA, and nonoxynol-9 on sperm motion parameters and acrosome status.
Centola, GM, 1998
)
" The model has been employed to optimize dosing regime of gramicidin S containing drug Grammidin."( Optimization of antimicrobial drug gramicidin S dosing regime using biosimulations.
Belashov, A; Demin, O; Smirnov, S, 2009
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1383354Induction of pore formation in DOPC vesicles at 20 uM after 3 hrs by carboxyfluorescein dye leakage assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383339Growth inhibition of multidrug-resistant Klebsiella pneumoniae ATCC 700603 at 32 ug/ml after 18 hrs2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383330Hemolytic activity against human RBC at 1.56 uM after 1 hr by Drabkin's assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383329Hemolytic activity against human RBC at 3.125 uM after 1 hr by Drabkin's assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1331164Antimicrobial activity against Proteus mirabilis ATCC 7002 after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1383351Growth inhibition of Candida albicans ATCC 90028 at 32 ug/ml after 24 hrs by resazurin dye-based microspectrophotometric method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1331171Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by NBT based LDH assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1331163Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1383335Hemolytic activity against human RBC after 1 hr by Drabkin's assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1331169Antimicrobial activity against Staphylococcus epidermidis PP62A after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1331162Hemolytic activity against human erythrocytes at 20 to 140 uM after 30 mins2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1331165Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1383345Antibacterial activity against multidrug-resistant Klebsiella pneumoniae ATCC 700603 after 18 hrs by polystyrene 96-well plate-based method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1331168Antimicrobial activity against Enterococcus faecium DSMZ 20477 after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1383328Hemolytic activity against human RBC at 6.25 uM after 1 hr by Drabkin's assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383331Hemolytic activity against human RBC at 0.78 uM after 1 hr by Drabkin's assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383334Hemolytic activity against human RBC2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1331167Antimicrobial activity against Enterococcus faecalis ATCC 29212 after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1331173Induction of bulk conductivity in soybean asolectin planar lipid bilayers assessed as residual conductance of black lipid bilayer at 0.5 nM at pH 82017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1331172Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1331166Antimicrobial activity against Streptococcus pneumoniae serotype 19A after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1383342Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by non-binding surface 96-well plate-based method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383337Growth inhibition of methicillin-resistant Staphylococcus aureus ATCC 43300 at 32 ug/ml after 18 hrs2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383344Antibacterial activity against multidrug-resistant Klebsiella pneumoniae ATCC 700603 after 18 hrs by non-binding surface 96-well plate-based method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383340Growth inhibition of Pseudomonas aeruginosa ATCC 27853 at 32 ug/ml after 18 hrs2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383347Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 18 hrs by polystyrene 96-well plate-based method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383349Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 18 hrs by polystyrene 96-well plate-based method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383327Hemolytic activity against human RBC at 12.5 uM after 1 hr by Drabkin's assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383332Hemolytic activity against human RBC at 0.39 uM after 1 hr by Drabkin's assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1331170Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by NBT based LDH assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1383352Growth inhibition of Cryptococcus neoformans H99 ATCC 208821 at 32 ug/ml after 24 hrs by resazurin dye-based microspectrophotometric assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383343Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by polystyrene 96-well plate-based method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383346Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 18 hrs by non-binding surface 96-well plate-based method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383353Induction of pore formation in POPC vesicles at 20 uM after 3 hrs by carboxyfluorescein dye leakage assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383338Growth inhibition of Escherichia coli ATCC 25922 at 32 ug/ml after 18 hrs2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383325Hemolytic activity against human RBC at 50 uM after 1 hr by Drabkin's assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383341Growth inhibition of Acinetobacter baumannii ATCC 19606 at 32 ug/ml after 18 hrs2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID1383350Antibacterial activity against Staphylococcus aureus after 16 to 20 hrs by microdilution method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1383326Hemolytic activity against human RBC at 25 uM after 1 hr by Drabkin's assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1331161Antimicrobial activity against Escherichia coli ATCC 25922 after 16 to 20 hrs by broth microdilution method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Bioactivity of topologically confined gramicidin A dimers.
AID1383348Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 18 hrs by non-binding surface 96-well plate-based method2018European journal of medicinal chemistry, Apr-10, Volume: 149Design, synthesis, and biological evaluation of stable β
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,628)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901044 (39.73)18.7374
1990's629 (23.93)18.2507
2000's574 (21.84)29.6817
2010's328 (12.48)24.3611
2020's53 (2.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (1.13%)5.53%
Reviews136 (4.97%)6.00%
Case Studies24 (0.88%)4.05%
Observational1 (0.04%)0.25%
Other2,545 (92.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]